2.64
-0.06 (-2.22%)
| Penutupan Terdahulu | 2.70 |
| Jumlah Dagangan | 9,525 |
| Harga / Jualan (P/S) | 4.29 |
| Harga / Buku (P/B) | 1.24 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -19,230.14% |
| EPS Cair (TTM) | -1.47 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -28.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.42% |
| Nisbah Semasa (MRQ) | 2.24 |
| Aliran Tunai Operasi (OCF TTM) | -8.69 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -3.84 M |
| Pulangan Atas Aset (ROA TTM) | -54.16% |
| Pulangan Atas Ekuiti (ROE TTM) | -117.16% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | BioRestorative Therapies, Inc. | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | 4.0 |
| Purata | -1.17 |
|
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 25.54% |
| % Dimiliki oleh Institusi | 12.62% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Wealth Alliance, Llc | 30 Jun 2026 | 2,000 |
| Keystone Financial Group | 30 Jun 2026 | 1,430 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |